clinical trial · NCT07620392
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Rheumatoid ArthritisAfimkibart
brief summary
The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.
started
Jun 3, 2026
primary completion
Jul 8, 2033
completion
Jul 8, 2033
last updated
Aug 21, 2026
official title
An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol